OBJECTIVE: To investigate prospectively whether autonomic nervous system (ANS) dysfunction and inflammation play a role in the increased cardiovascular disease (CVD)-related mortality risk associated with depression. METHODS: Participants in the Cardiovascular Health Study (n = 907; mean age, 71.3 ± 4.6 years; 59.1% women) were evaluated for ANS indices derived from heart rate variability (HRV) analysis (frequency and time domain HRV, and nonlinear indices, including detrended fluctuation analysis (DFA(1)) and heart rate turbulence). Inflammation markers included C-reactive protein, interleukin-6, fibrinogen, and white blood cell count). Depressive symptoms were assessed, using the 10-item Centers for Epidemiological Studies Depression scale. Cox proportional hazards models were used to investigate the mortality risk associated with depression, ANS, and inflammation markers, adjusting for demographic and clinical covariates. RESULTS: Depression was associated with ANS dysfunction (DFA(1), p = .018), and increased inflammation markers (white blood cell count, p = .012, fibrinogen p = .043) adjusting for covariates. CVD-related mortality occurred in 121 participants during a median follow-up of 13.3 years. Depression was associated with an increased CVD mortality risk (hazard ratio, 1.88; 95% confidence interval, 1.23-2.86). Multivariable analyses showed that depression was an independent predictor of CVD mortality (hazard ratio, 1.72; 95% confidence interval, 1.05-2.83) when adjusting for independent HRV and inflammation predictors (DFA(1), heart rate turbulence, interleukin-6), attenuating the depression-CVD mortality association by 12.7% (p < .001). CONCLUSION: Autonomic dysfunction and inflammation contribute to the increased cardiovascular mortality risk associated with depression, but a large portion of the predictive value of depression remains unexplained by these neuroimmunological measures.
OBJECTIVE: To investigate prospectively whether autonomic nervous system (ANS) dysfunction and inflammation play a role in the increased cardiovascular disease (CVD)-related mortality risk associated with depression. METHODS:Participants in the Cardiovascular Health Study (n = 907; mean age, 71.3 ± 4.6 years; 59.1% women) were evaluated for ANS indices derived from heart rate variability (HRV) analysis (frequency and time domain HRV, and nonlinear indices, including detrended fluctuation analysis (DFA(1)) and heart rate turbulence). Inflammation markers included C-reactive protein, interleukin-6, fibrinogen, and white blood cell count). Depressive symptoms were assessed, using the 10-item Centers for Epidemiological Studies Depression scale. Cox proportional hazards models were used to investigate the mortality risk associated with depression, ANS, and inflammation markers, adjusting for demographic and clinical covariates. RESULTS:Depression was associated with ANS dysfunction (DFA(1), p = .018), and increased inflammation markers (white blood cell count, p = .012, fibrinogen p = .043) adjusting for covariates. CVD-related mortality occurred in 121 participants during a median follow-up of 13.3 years. Depression was associated with an increased CVD mortality risk (hazard ratio, 1.88; 95% confidence interval, 1.23-2.86). Multivariable analyses showed that depression was an independent predictor of CVD mortality (hazard ratio, 1.72; 95% confidence interval, 1.05-2.83) when adjusting for independent HRV and inflammation predictors (DFA(1), heart rate turbulence, interleukin-6), attenuating the depression-CVD mortality association by 12.7% (p < .001). CONCLUSION:Autonomic dysfunction and inflammation contribute to the increased cardiovascular mortality risk associated with depression, but a large portion of the predictive value of depression remains unexplained by these neuroimmunological measures.
Authors: Mikko P Tulppo; Antti M Kiviniemi; Arto J Hautala; Mika Kallio; Tapio Seppänen; Timo H Mäkikallio; Heikki V Huikuri Journal: Circulation Date: 2005-07-11 Impact factor: 29.690
Authors: François Lespérance; Nancy Frasure-Smith; Diana Koszycki; Marc-André Laliberté; Louis T van Zyl; Brian Baker; John Robert Swenson; Kayhan Ghatavi; Beth L Abramson; Paul Dorian; Marie-Claude Guertin Journal: JAMA Date: 2007-01-24 Impact factor: 56.272
Authors: Naomi M Simon; Zandra E Walton; Eric Bui; Jennifer Prescott; Elizabeth Hoge; Aparna Keshaviah; Noah Schwarz; Taylor Dryman; Rebecca A Ojserkis; Benjamin Kovachy; David Mischoulon; John Worthington; Immaculata De Vivo; Maurizio Fava; Kwok-Kin Wong Journal: Psychoneuroendocrinology Date: 2015-04-13 Impact factor: 4.905
Authors: Junichiro Hayano; Robert M Carney; Eiichi Watanabe; Kiyohiro Kawai; Itsuo Kodama; Phyllis K Stein; Lana L Watkins; Kenneth E Freedland; James A Blumenthal Journal: Psychosom Med Date: 2012-09-28 Impact factor: 4.312
Authors: Mary C Vance; Eric Bui; Susanne S Hoeppner; Benjamin Kovachy; Jennifer Prescott; David Mischoulon; Zandra E Walton; Melissa Dong; Mireya F Nadal; John J Worthington; Elizabeth A Hoge; Paolo Cassano; Esther H Orr; Maurizio Fava; Immaculata de Vivo; Kwok-Kin Wong; Naomi M Simon Journal: Psychoneuroendocrinology Date: 2018-02-21 Impact factor: 4.905
Authors: A H Khandoker; V Luthra; Y Abouallaban; S Saha; K I Ahmed; R Mostafa; N Chowdhury; H F Jelinek Journal: Med Biol Eng Comput Date: 2016-08-18 Impact factor: 2.602
Authors: Martica H Hall; Kellie Middleton; Julian F Thayer; Tené T Lewis; Christopher E Kline; Karen A Matthews; Howard M Kravitz; Robert T Krafty; Daniel J Buysse Journal: Psychosom Med Date: 2013-09-27 Impact factor: 4.312
Authors: Amjad M Ahmed; Waqas T Qureshi; Sherif Sakr; Michael J Blaha; Clinton A Brawner; Jonathan K Ehrman; Steven J Keteyian; Mouaz H Al-Mallah Journal: Clin Cardiol Date: 2018-04-17 Impact factor: 2.882